OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Patel on Remaining Gaps in Biomarker Testing for Early-Stage Resected NSCLC

September 8th 2025

Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.

Dr Nieva on the Role of ADCs in the NSCLC Treatment Paradigm

September 8th 2025

Jorge Nieva, MD, discusses the current role and the effect antibody-drug conjugates have on the lung cancer treatment paradigm.

Dr Singhi on Responsibly and Effectively Leveraging Social Media for Patient Education in Oncology

September 8th 2025

Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.

Dr Popat on the Rationale for Assessing JNJ-5322 in Relapsed/Refractory Myeloma

September 8th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the mechanism of action and the impetus for assessing JNJ-5322 in relapsed/refractory multiple myeloma.

Dr Taub on the Benefits of a Multimodal Treatment Approach in Prostate Cancer

September 8th 2025

David Taub, MD, FACS, discusses how multidisciplinary care can optimize therapy selection for patients across different stages of prostate cancer.

Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1+ NSCLC

September 7th 2025

Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.

Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC

September 7th 2025

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

Dr Issa on Testing for NPM1 or KMT2A Alterations in AML

September 6th 2025

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Dr Gangaram-Panday on Definitive Chemoradiotherapy in Esophageal Cancer

September 5th 2025

Sanjiv Gangaram-Panday, PhD, discusses findings from a population-based cohort study of definitive chemoradiotherapy in esophageal adenocarcinoma.

Dr Eng on the Implications of a Real-World Study in KRAS G12C–Mutated CRC

September 5th 2025

Cathy Eng, MD, FACP, FASCO, discusses the clinical significance of a real-world study of KRAS G12C mutations on treatment outcomes in mCRC.

Dr Shadman on the Impetus for Assessing Zanubrutinib Plus Venetoclax in Previously Untreated CLL/SLL

September 5th 2025

Mazyar Shadman, MD, MPH, details the rationale for investigating the combination of zanubrutinib and venetoclax in treatment-naive CLL/SLL.

Dr Sfakianos on Addressing Unmet Needs With Intravesical Mitomycin in Recurrent, Low-Grade, Intermediate-Risk NMIBC

September 5th 2025

John P. Sfakianos, MD, discusses the rationale for evaluating mitomycin intravesical solution in recurrent, low-grade, intermediate-risk NMIBC.

Dr O’Shaughnessy on the Utility of the MammaPrint Assay in HR+ Breast Cancer

September 5th 2025

Joyce O’Shaughnessy, MD, discussed data that support the use of the MammaPrint assay in predicting chemotherapy benefit in HR-positive breast cancer.

Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis

September 5th 2025

Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.

Dr Loghavi on SOC Frontline Testing Approaches in MDS

September 5th 2025

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.

Dr McKay on the Rationale for Evaluating Radium-223 Plus Olaparib in mCRPC With Bone Metastases

September 5th 2025

Rana R. McKay, MD, discusses unmet needs in mCRPC that led to the inception of the COMRADE trial.

Dr Jagannath on the Potential Role of MRD Testing for Defining "Cure" in Myeloma

September 5th 2025

Sundar Jagannath, MBBS, explores how minimal residual disease could redefine what it means to achieve a "cure" in multiple myeloma.

Dr Palandri on Efforts to Elucidate the Role of Predictive Markers for Ruxolitinib in Myelofibrosis

September 5th 2025

Francesca Palandri, MD, discusses research needed to clarify the role of predictive markers for ruxolitinib response in myelofibrosis.

Dr Gellhaus on the Significance of Prostate Cancer Awareness Month

September 4th 2025

Paul Gellhaus, MD, discusses the clinical implications of prostate cancer screening in recognition of Prostate Cancer Awareness Month.

Dr Sands on Toxicities Associated With Tarlatamab in SCLC

September 4th 2025

Jacob Sands, MD, discusses ways to manage the toxicities associated with the DLL3 inhibitor tarlatamab in the treatment of patients with SCLC.